PTCT vs BMRN Comparison: AI Score, Valuation, Performance and Upside
Compare PTC Therapeutics and BioMarin by Duchenne muscular dystrophy and PKU drug portfolios, regulatory pathway history, revenue growth trajectory, and which mid-cap rare disease biotech offers better risk-adjusted returns.
Use this PTC Therapeutics vs BioMarin comparison to evaluate the key differences across valuation, growth, profitability, and risk before making an investment decision.
PTCT and BMRN are closely matched — they split the tracked metrics evenly. PTCT has delivered stronger 1-year price return (+65.85% vs -0.72%), though BMRN has the better forward P/E setup (9.28x vs 28.04x for PTCT). Analyst consensus implies meaningfully more upside for BMRN (+48.19%) than for PTCT (+25.06%).
| Metric | PTCT | BMRN |
|---|---|---|
| AI score | 53.4 | 26.9 |
| AI rank | #319 | #2535 |
| Latest close | $76.82 | $59.33 |
| 1M return | -8.99% | +3.49% |
| 6M return | +0.85% | +3.76% |
| 1Y return | +65.85% | -0.72% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | PTCT | BMRN |
|---|---|---|
| 1Y ago | $16.58K (+65.8%) started 2025-07-24 | $9.93K (-0.7%) started 2025-07-24 |
| 5Y ago | $19.14K (+91.4%) started 2021-07-26 | $7.67K (-23.3%) started 2021-07-26 |
| 10Y ago | $113.64K (+1036.4%) started 2016-07-25 | $6.39K (-36.1%) started 2016-07-25 |
Hypothetical — past performance does not guarantee future results.
| Metric | PTCT | BMRN |
|---|---|---|
| Market cap | $6.37B | $11.47B |
| Trailing P/E | N/A | 42.68 |
| Forward P/E | 28.04 | 9.28 |
| Price/Sales | 7.70 | 3.54 |
| EV/Revenue | 8.87 | 3.27 |
| Analyst target | $96.07 | $87.92 |
| Target upside | +25.06% | +48.19% |
| Metric | PTCT | BMRN |
|---|---|---|
| Revenue growth | -76.80% | 2.80% |
| Earnings growth | N/A | -43.10% |
| EPS growth | N/A | -43.10% |
| FCF margin | -50.55% | +14.17% |
| Operating margin | N/A | N/A |
| Profit margin | -22.58% | 8.29% |
| ROIC proxy | N/A | 4.48% |
| Return on equity | N/A | 4.48% |
| Dividend yield | 0.00% | 0.00% |
| Beta | 0.53 | 0.24 |
| Debt/equity | N/A | 23.17 |
| Current ratio | 2.44 | 5.81 |
| Quick ratio | 2.29 | 3.94 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | PTCT | BMRN |
|---|---|---|---|
| 1Y | Growth | +65.85% | -0.72% |
| CAGR | +65.90% | -0.72% | |
| Sharpe ratio | 1.28 | 0.01 | |
| Max drawdown | 27.17% | 22.49% | |
| Max daily drop | 9.89% | 4.35% | |
| Max wkly drop | 17.13% | 8.75% | |
| 5Y | Growth | +91.38% | -23.30% |
| CAGR | +13.88% | -5.17% | |
| Sharpe ratio | 0.43 | -0.13 | |
| Max drawdown | 69.42% | 57.64% | |
| Max daily drop | 29.77% | 17.71% | |
| Max wkly drop | 39.59% | 17.74% | |
| 10Y | Growth | +1036.39% | -36.06% |
| CAGR | +27.53% | -4.38% | |
| Sharpe ratio | 0.62 | -0.08 | |
| Max drawdown | 73.78% | 62.09% | |
| Max daily drop | 39.94% | 35.28% | |
| Max wkly drop | 48.27% | 38.91% |
| Category | PTCT | BMRN |
|---|---|---|
| Company | PTCT | BMRN |
| Sector | N/A | N/A |
| Industry | N/A | N/A |
| Core business | N/A | N/A |
| Investor focus | N/A | N/A |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.